{
}
CRISPR Therapeutics AG's stock has fallen to a 52-week low of $38.2, reflecting a 38.23% decline over the past year amid investor concerns about regulatory challenges and clinical trial progress. Despite a strong balance sheet with more cash than debt, analysts have mixed views, with targets ranging from $30 to $268. The company is advancing its gene editing pipeline, including the launch of CASGEVY® and ongoing trials for CTX112™ and CTX131™, while planning to appoint Briggs Morrison, M.D., to its Board of Directors.
CRISPR Therapeutics, trading at $39.69 with a market cap of $3.39 billion, is focusing on the launch of its gene-based medicine CASGEVY® and advancing its gene editing pipeline. The company reported operating expenses of $110.1 million and a cash position of $1.94 billion, while analysts hold mixed ratings. Key developments include ongoing clinical trials for CTX112™ and CTX131™, with updates expected in 2025, alongside a strong demand for CASGEVY® following its regulatory approval for sickle cell disease and beta thalassemia.
CRISPR Therapeutics has proposed the election of Briggs Morrison, M.D., to its Board of Directors at the upcoming annual general meeting. With over 30 years in the pharmaceutical industry, Morrison brings extensive experience in clinical development, having overseen the approval of several notable drugs. He expressed enthusiasm for joining the innovative company and contributing to its mission of developing transformative gene-based medicines.
CRISPR Therapeutics has proposed the election of Briggs Morrison, M.D., to its Board of Directors at the upcoming annual general meeting. With over 30 years in the pharmaceutical industry, including leadership roles at AstraZeneca and Pfizer, Morrison's expertise in clinical development is expected to enhance the company's innovative pipeline. He has overseen the development of notable drugs such as Tagrisso®, Imfinzi®, and Lynparza®.
[SEC](https://www.sec.gov) or [Bloomberg]
CRISPR Therapeutics has proposed the election of Briggs Morrison, M.D., to its Board of Directors at the upcoming annual general meeting. With over 30 years in the pharmaceutical industry, Morrison's expertise in clinical development is expected to enhance the company's innovative gene-based medicine initiatives. CRISPR Therapeutics, which celebrated the approval of the first CRISPR-based therapy in 2023, continues to advance its diverse portfolio targeting serious diseases.
Briggs Morrison
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
CRISPR Therapeutics stock falls to 52-week low amid biotech market challenges
16:09 13.01.2025
CRISPR Therapeutics sets ambitious 2025 goals amid strong market presence
United States Dollar
Vertex Pharmaceuticals Inc
CRISPR Therapeutics AG
CHE
Briggs Morrison
Samarth Kulkarni
13:10 13.01.2025
crispr therapeutics proposes briggs morrison for board of directors
United States Dollar
Pfizer Inc.
AstraZeneca PLC
CRISPR Therapeutics AG
Merck & Co., Inc.
USA
Briggs Morrison
Samarth Kulkarni
Show more
14:04 07.01.2025
crispr therapeutics proposes briggs morrison for board of directors election
United States Dollar
Vertex Pharmaceuticals Inc
AstraZeneca PLC
Bayer AG
Pfizer Inc.
Syndax Pharmaceuticals, Inc.
Merck & Co., Inc.
CHE
Briggs Morrison
Samarth Kulkarni
Show more
14:00 07.01.2025
crispr therapeutics proposes briggs morrison for board of directors appointment
14:00 07.01.2025
CRISPR Therapeutics nominates Briggs Morrison for Board of Directors position
14:00 07.01.2025
Trending
Subcategory
Corporate News
Industry Trends
Emerging Startups
Venture Capital Investments
Startups & Entrepreneurship
Funding Rounds & Investments
Fintech Startups
AI Innovations
Economic Indicators
Retail and Consumer Goods
Global Trade Developments
Government Economic Policies
Cryptocurrency Trends
Product Launches
IPOs & SPACs
Private Equity Deals
AI Applications
Macro-economic Trends
Supply Chain Management
Industry Mergers & Acquisitions
Countries:
Companies:
Apple Inc.
Nvidia Corporation
NVIDIA Corporation
Microsoft Corporation
SWIGGY LIMITED
Vecmocon Technologies Ltd.
VOLKSWAGEN AG
Amazon.com Inc.
Medius Holdings Co., Ltd.
SITC International Holdings Company Limited
Firefly AB (publ)
Aeon Bank (M) Berhad Bhd
AF DOBRA, SICAV, S.A.
Alibaba Group Holding Limited
Getty Images Holdings, Inc.
Sunnova Energy International Inc.
QUALCOMM Incorporated
Alphawave IP Group plc
Grab2Go AS
HDB Financial Services Ltd.
Currencies:
People: